Drug
25 Mci 177lu Dtpa Omburtamab
25 Mci 177lu Dtpa Omburtamab: highest development phase Phase 1, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| 25 mCi 177Lu- DTPA-omburtamab NCT07698899 | Phase 1 | Recurrent Medulloblastoma |
Latest
No recent events.
Follow 25 Mci 177lu Dtpa Omburtamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.